Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
82 hedge funds and large institutions have $270M invested in Chinook Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 14 closing their positions.
470% more call options, than puts
Call options by funds: $974K | Put options by funds: $171K
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
2% less capital invested
Capital invested by funds: $275M → $270M (-$4.85M)
6% less funds holding
Funds holding: 87 → 82 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$35.7M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$9.04M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.95M |
| 4 |
Goldman Sachs
New York
|
+$2.05M |
| 5 |
Renaissance Technologies
New York
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.47M |
| 3 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$2.21M |
| 4 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
-$608K |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$589K |
KDNY Hedge Fund Activity: Q1 2017 in Review
82 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2017, worth a combined $270M — down 1.8% from $275M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KDNY positions and 14 closed out — a net gain of 1 holder — while 27 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $35.7M. The largest seller was BVF Inc, exiting entirely with an estimated $8.5M sold.
- 82 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2017, down from 87 in Q4 2016.
- Funds reported $270M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2017, down 1.8% quarter-over-quarter.
- 15 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2017 and 14 closed out, a net change of +1 holder.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $35.7M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2017 was BVF Inc, an estimated $8.5M sold.
Based on aggregated 13F filings for Q1 2017.